BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options
Article excerpt
Highlighted: the sentence this signal was extracted from
The launch of the Liverty™ TIPS Stent Graft gives physicians flexibility to tailor treatment for patients. FRANKLIN LAKES, N.J. , Oct. 28, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the U.S. commercial launch of the BD ® Liverty™ TIPS Stent Graft, advancing portal hypertension care by giving physicians greater flexibility to tailor treatment to each patient's hemodynamic needs. The next generation transjugular intrahepatic portosystemic shunt (TIPS) system is designed to provide physicians with deployment accuracy and control, and the flexibility to tailor treatment based on individual patient anatomy, disease progression and clinical goals. The product enters the U.S. market with established clinical and physician experience in Europe and is supported by the six-month interim results from the 177 patient, prospective, multi-center ARCH clinical study, the first and only IDE study with small TIPS diameter (6-7 mm) clinical data. TIPS is a minimally invasive procedure used to create a new pathway for blood flow in the liver, helping relieve pressure caused by portal hypertension, a condition that can lead to serious complications such as internal bleeding or fluid buildup in the abdomen. TIPS procedures are used to manage conditions such as variceal bleeding and refractory ascites, but can...
Keep reading with a free account
The rest of this article, and every signal for BD, is in your free account.
